<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="35664">Statins</z:chebi> may exert pleiotropic effects on insulin action that are still controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed effects of high-dose <z:chebi fb="0" ids="9150">simvastatin</z:chebi> therapy on peripheral and hepatic insulin sensitivity, as well as on ectopic <z:mpath ids='MPATH_42'>lipid deposition</z:mpath> in patients with <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We performed a randomized, double-blind, placebo-controlled, single-center study </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> received 80 mg <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (BMI 29 +/- 4 kg/m2, age 55 +/- 6 years) or placebo (BMI 27 +/- 4 kg/m2, age 58 +/- 8 years) daily for 8 weeks and were compared with 10 healthy humans (control subjects; BMI 27 +/- 4 kg/m2, age 55 +/- 7 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Euglycemic-hyperinsulinemic clamp tests combined with D-[6,6-d2]<z:chebi fb="105" ids="17234">glucose</z:chebi> infusion were used to assess insulin sensitivity (M) and endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) </plain></SENT>
<SENT sid="5" pm="."><plain>1H magnetic resonance spectroscopy was used to quantify intramyocellular and hepatocellular <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: High-dose <z:chebi fb="0" ids="9150">simvastatin</z:chebi> treatment lowered plasma total and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> levels by approximately 33 and approximately 48% (P &lt; 0.005) but did not affect M, intracellular <z:mpath ids='MPATH_42'>lipid deposition</z:mpath> in soleus and tibialis anterior muscles and liver, or basal and insulin-suppressed EGP </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:chebi fb="0" ids="9150">simvastatin</z:chebi>-treated patients, changes in <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> related negatively to changes in M (r = -0.796, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Changes in fasting free fatty acids (FFAs) related negatively to changes in M (r = -0.840, P &lt; 0.01) and positively to plasma <z:chebi fb="1" ids="50211">retinol</z:chebi>-binding protein-4 (r = 0.782, P = 0.008) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: High-dose <z:chebi fb="0" ids="9150">simvastatin</z:chebi> treatment has no direct effects on whole-body or tissue-specific insulin action and ectopic <z:mpath ids='MPATH_42'>lipid deposition</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>A reduction in plasma FFAs probably mediates alterations in insulin sensitivity in vivo </plain></SENT>
</text></document>